Mobile App Logging for Diabetes in Pregnancy
Launched by CAROLYN ZAHLER-MILLER · Aug 16, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how using a mobile app to track blood sugar levels compares to using paper logs for pregnant women with diabetes. The goal is to see if the app helps women keep better track of their blood sugar levels, which is important for both their health and their baby's health. This study is open to women aged 18 and older who are at least 12 weeks pregnant and have been diagnosed with either gestational diabetes or type 2 diabetes.
If you decide to participate, you will be asked to monitor your blood sugar levels either through a mobile app or by using paper logs. The trial is currently recruiting participants, so if you meet the criteria and are interested, you can get involved. It's important to note that women who have type 1 diabetes or are already using a continuous glucose monitor or another app for tracking their glucose levels cannot participate. This trial could help improve diabetes management for pregnant women in the future!
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 18 years and older
- • Verified intrauterine pregnancy
- • At least 12 weeks gestation
- • Diagnosed with either type 2 diabetes mellitus or gestational diabetes mellitus.
- Exclusion Criteria:
- • Patients with less than 4 weeks anticipated to be remaining in pregnancy
- • Pre-existing use of a continuous glucose monitor or other mobile application for glucose tracking
- • Type 1 diabetes mellitus
- • Non-English speaking patients
About Carolyn Zahler Miller
Carolyn Zahler-Miller is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in the healthcare sector, she focuses on the strategic design and execution of clinical trials that adhere to rigorous ethical standards and regulatory compliance. Carolyn excels in fostering collaboration among multidisciplinary teams, ensuring that innovative therapies are rigorously evaluated for safety and efficacy. Her leadership is characterized by a patient-centered approach, prioritizing transparency and integrity throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Augusta, Georgia, United States
Patients applied
Trial Officials
Rebecca Keipper, MD
Principal Investigator
Augusta University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported